{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:08:14Z","timestamp":1790204894577,"version":"4.1.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5U01AI069919"],"award-info":[{"award-number":["5U01AI069919"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA 2016 CDF 1597"],"award-info":[{"award-number":["TMA 2016 CDF 1597"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0236642","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:51:58Z","timestamp":1596649918000},"page":"e0236642","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d\u2019Ivoire West Africa"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-9610","authenticated-orcid":true,"given":"Boris K.","family":"Tchounga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Coffie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge P.","family":"Eholie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier K.","family":"Ekouevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"pone.0236642.ref001","article-title":"Hiv-2 molecular epidemiology","author":"B Visseaux","year":"2016","journal-title":"Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis"},{"issue":"4","key":"pone.0236642.ref002","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1099\/vir.0.038638-0","article-title":"Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A","volume":"93","author":"NR Faria","year":"2012","journal-title":"J Gen Virol"},{"issue":"6","key":"pone.0236642.ref003","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on human immunodeficiency virus (HIV)-2 infection","volume":"52","author":"OT Campbell-Yesufu","year":"2011","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"22","key":"pone.0236642.ref004","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.222366699","article-title":"Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors","volume":"99","author":"J Ren","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0236642.ref005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis","volume":"9","author":"M Witvrouw","year":"2004","journal-title":"Antivir Ther"},{"issue":"10","key":"pone.0236642.ref006","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/cir123","article-title":"Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group","volume":"52","author":"A Benard","year":"2011","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"16","key":"pone.0236642.ref007","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e32830edd44","article-title":"A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa","volume":"22","author":"GS Gottlieb","year":"2008","journal-title":"AIDS"},{"issue":"16","key":"pone.0236642.ref008","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1097\/QAD.0b013e32830edd59","article-title":"HIV-2 infection: a call for controlled trials","volume":"22","author":"S Matheron","year":"2008","journal-title":"AIDS"},{"key":"pone.0236642.ref009","volume-title":"WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"WHO","year":"2013"},{"key":"pone.0236642.ref010","first-page":"18","volume-title":"Prise en charge m\u00e9dicale des personnes vivant avec le VIH Infection VIH-2; Diversit\u00e9 des VIH-1","author":"P Morlat","year":"2016"},{"key":"pone.0236642.ref011","first-page":"288","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV:","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2017"},{"issue":"10","key":"pone.0236642.ref012","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1468-1293.2010.00889.x","article-title":"British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010","volume":"11","author":"Y Gilleece","year":"2010","journal-title":"HIV Med"},{"key":"pone.0236642.ref013","first-page":"16","volume-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"WHO","year":"2019"},{"key":"pone.0236642.ref014","article-title":"Directives nationales 2015 de Prise En Charge des Personnes Vivant avec le VIH","author":"PNLS C\u00f4te d\u2019Ivoire","year":"2015","journal-title":"Programme National de Lutte contre le Sida (PNLS)"},{"issue":"8","key":"pone.0236642.ref015","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000000244","article-title":"Genotypic resistance profiles of HIV-2-treated patients in West Africa","volume":"28","author":"C Charpentier","year":"2014","journal-title":"AIDS Lond Engl"},{"issue":"4","key":"pone.0236642.ref016","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/596504","article-title":"Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa","volume":"48","author":"GS Gottlieb","year":"2009","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"6","key":"pone.0236642.ref017","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00405-13","article-title":"Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy","volume":"57","author":"DN Raugi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0236642.ref018","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1128\/JCM.01654-08","article-title":"Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants","volume":"47","author":"S Jallow","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"4","key":"pone.0236642.ref019","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/135965350400900422","article-title":"Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen","volume":"9","author":"F Damond","year":"2004","journal-title":"Antivir Ther"},{"issue":"15","key":"pone.0236642.ref020","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1097\/QAD.0b013e32830f4c7d","article-title":"Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen","volume":"22","author":"B Roquebert","year":"2008","journal-title":"AIDS Lond Engl"},{"issue":"10","key":"pone.0236642.ref021","first-page":"1521","article-title":"Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program","volume":"60","author":"D Descamps","year":"2015","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"6","key":"pone.0236642.ref022","doi-asserted-by":"crossref","first-page":"e66135","DOI":"10.1371\/journal.pone.0066135","article-title":"Characteristics of HIV-2 and HIV-1\/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study","volume":"8","author":"DK Ekouevi","year":"2013","journal-title":"PloS One"},{"key":"pone.0236642.ref023","first-page":"JCM.00724","article-title":"A new sensitive one-step real-time duplex PCR method for groups A and B HIV-2 RNA load","author":"V Avettand-Fenoel","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"1","key":"pone.0236642.ref024","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.05313-11","article-title":"In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors","volume":"56","author":"B Visseaux","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0236642.ref025","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"B Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"17","key":"pone.0236642.ref026","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","article-title":"In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572","volume":"24","author":"C Charpentier","year":"2010","journal-title":"AIDS Lond Engl"},{"key":"pone.0236642.ref027","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12977-015-0146-8","article-title":"In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2","volume":"12","author":"RA Smith","year":"2015","journal-title":"Retrovirology"},{"issue":"9","key":"pone.0236642.ref028","doi-asserted-by":"crossref","first-page":"e45372","DOI":"10.1371\/journal.pone.0045372","article-title":"Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens","volume":"7","author":"RA Smith","year":"2012","journal-title":"PLOS ONESep 18"},{"issue":"9","key":"pone.0236642.ref029","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/tmi.12746","article-title":"Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy","volume":"21","author":"G Waldrop","year":"2016","journal-title":"Trop Med Int Health TM IH"},{"issue":"2","key":"pone.0236642.ref030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcv.2012.06.024","article-title":"Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform","volume":"55","author":"M Chang","year":"2012","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"pone.0236642.ref031","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jcv.2013.09.007","article-title":"Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control","volume":"1","author":"LM Styer","year":"2013","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"pone.0236642.ref032","first-page":"463704","article-title":"Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings","volume":"2011","author":"K Peterson","year":"2011","journal-title":"AIDS Res Treat"},{"key":"pone.0236642.ref033","article-title":"Mortality and survival patterns of people living with HIV-2","author":"B Tchounga","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"pone.0236642.ref034","article-title":"Effect of sex and age on outcomes among hiv-2 infected patients starting antiretroviral therapy in west africa: a multicentre cohort study","author":"BK Tchounga","year":"2016","journal-title":"AIDS Lond Engl"},{"issue":"6","key":"pone.0236642.ref035","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3851\/IMP1826","article-title":"Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal","volume":"16","author":"C Charpentier","year":"2011","journal-title":"Antivir Ther"},{"issue":"2","key":"pone.0236642.ref036","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1128\/JVI.06155-11","article-title":"Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection","volume":"86","author":"R Kong","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"pone.0236642.ref037","first-page":"49","article-title":"HIV-2 susceptibility to entry inhibitors","volume":"15","author":"P Borrego","year":"2013","journal-title":"AIDS Rev"},{"issue":"10","key":"pone.0236642.ref038","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/jac\/dks240","article-title":"Long-term maraviroc use as salvage therapy in HIV-2 infection","volume":"67","author":"U Caixas","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"pone.0236642.ref039","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/cid\/ciy245","article-title":"First-line Raltegravir\/Emtricitabine\/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)","volume":"67","author":"S Matheron","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"10","key":"pone.0236642.ref040","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciy324","article-title":"A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa","volume":"67","author":"S Ba","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"pone.0236642.ref041","first-page":"82","volume-title":"UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV","author":"World Health Organization","year":"2018"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T21:16:04Z","timestamp":1667682964000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236642"}},"subtitle":[],"editor":[{"given":"Cristian","family":"Apetrei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0236642","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]}}}